Nolva-Med, Tamoxifen, 20 mg, 60 Tabs

Tamoxifen Citrate 20 mg by Bioniche Pharma is an orally bioavailable non-steroidal Selective Estrogen Receptor Modulator (SERM). Formulated by Bioniche Pharma for high target-receptor binding affinity, Bioniche Pharma Tamoxifen Citrate exhibits tissue-specific anti-estrogenic and agonist effects to manage hormone-sensitive cellular proliferation and endocrine pathways.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Tamoxifen Citrate in Bioniche Pharma Tamoxifen competitively binds to intracellular estrogen receptors (ER) across target tissues and tumor cells. Following receptor binding, the drug-receptor complex migrates into the cell nucleus to block transcription factors, inhibit cellular DNA synthesis, and arrest estrogen-driven cell growth. Bioniche Pharma Tamoxifen Citrate displays tissue-selective pharmacological behavior, acting as a potent antagonist in mammary tissue while demonstrating partial estrogenic agonist properties in endometrial and bone tissues.

INDICATIONS & CLINICAL USE

• Adjuvant and palliative treatment of early and advanced estrogen receptor-positive (ER+) breast carcinoma in pre-menopausal and post-menopausal female patients using Bioniche Pharma Tamoxifen Citrate.
• Prophylactic management to reduce the risk of breast cancer in high-risk female populations under clinical direction.
• Risk reduction for contralateral breast cancer development in diagnosed patients following Bioniche Pharma treatment protocols.

CONTRAINDICATIONS

• Known hypersensitivity or allergic reaction to Tamoxifen Citrate or inactive compounding excipients in Bioniche Pharma formulations.
• Pregnancy, planned pregnancy, and lactation due to high risks of teratogenicity, fetal harm, and developmental toxicity.
• Active thromboembolic conditions or a documented clinical history of deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Severe hepatic impairment, advanced liver failure, or active biliary disease.

ADVERSE REACTIONS & PRECAUTIONS

Routine clinical oversight is advised during Bioniche Pharma Tamoxifen Citrate therapy to monitor for estrogen deprivation features and systemic adverse events:

• Vasomotor & Gynecological: Hot flashes, vaginal discharge or spotting, pruritus vulvae, and pelvic pressure associated with Bioniche Pharma Tamoxifen Citrate administration.
• Gastrointestinal & Neurological: Mild nausea, emesis, headaches, lightheadedness, generalized fatigue, and transient tumor site discomfort during the initial treatment phase with Bioniche Pharma Tamoxifen Citrate.
• Fluid Balance & Dermatological: Fluid retention, peripheral edema, skin rashes, and transient hair thinning (alopecia) linked to Bioniche Pharma therapy.
• Hepatic & Biliary: Transient transaminase elevations, hepatic steatosis, impaired bile secretion (cholestasis), and localized liver inflammation. Routine hepatic function panels are recommended during Bioniche Pharma Tamoxifen Citrate treatment.

DOSAGE & ADMINISTRATION

Dosing protocols for Tamoxifen Citrate by Bioniche Pharma should be individually calculated and managed under direct oncological direction based on tumor staging, hormonal receptor status, and treatment goals.

STORAGE & HANDLING

Store Bioniche Pharma Tamoxifen Citrate in a dry, cool location protected from direct light exposure, elevated heat, and moisture. Store safely out of the reach and sight of children.